Bluebird bio, Inc. Bluebird bio, Inc.

Bluebird bio, Inc.

BLUE

Classement en actions #15676
bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery,... bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments are aimed at debilitating genetic conditions. Among its leading investigational therapies for severe inherited diseases are betibeglogene autotemcel (beti-cel), intended for patients with transfusion-dependent beta-thalassemia; lovotibeglogene autotemcel (lovo-cel), which targets sickle cell disease (SCD); and elivaldogene autotemcel (eli-cel), developed to address cerebral adrenoleukodystrophy. The company's robust clinical trial program is actively evaluating the safety and efficacy of these treatments. Specifically, lovo-cel's impact on SCD patients is being assessed in studies HGB-205, HGB-206, and HGB-210. Concurrently, beti-cel is under investigation for beta-thalassemia in trials HGB-204, HGB-205, HGB-207, and HGB-212. Furthermore, bluebird bio maintains strategic collaborations and licensing arrangements with entities such as Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company, which began its operations in 1992, was formerly known as Genetix Pharmaceuticals, Inc., and rebranded as bluebird bio, Inc. in September 2010. Its principal office is located in Cambridge, Massachusetts.
Prix de l'action
$4.97
Dernière synchronisation: 2025-06-02
Capitalisation boursière
$318.62M
Changement (1 jour)
0.00%
Changement (1 an)
-38.03%
Pays
US
Échange Bluebird bio, Inc. (BLUE)

Catégorie

Healthcare
Ratio P/S pour Bluebird bio, Inc. (BLUE)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Bluebird bio, Inc., le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Bluebird bio, Inc. de 2026 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
Pas assez de données pour les dates fournies.
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.02 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
40.55 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.96 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.15 -
NL